Zhejiang Tianyu Pharmaceutical Co., Ltd.

SZSE:300702 Stock Report

Market Cap: CN¥5.8b

Zhejiang Tianyu Pharmaceutical Future Growth

Future criteria checks 4/6

Zhejiang Tianyu Pharmaceutical is forecast to grow earnings and revenue by 40.4% and 18.6% per annum respectively while EPS is expected to grow by 39.9% per annum.

Key information

40.4%

Earnings growth rate

39.9%

EPS growth rate

Pharmaceuticals earnings growth19.3%
Revenue growth rate18.6%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Jun 2024

Recent future growth updates

Recent updates

We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt

Nov 04
We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt

Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance

Sep 04
Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance

Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)

Aug 21
Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)

Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce

May 21
Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce

Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors

Mar 17
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors

Earnings and Revenue Growth Forecasts

SZSE:300702 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253,345196N/A1231
12/31/20242,920264N/A3211
9/30/20242,59544239425N/A
6/30/20242,44612129309N/A
3/31/20242,440-32-120118N/A
12/31/20232,52727-361-44N/A
9/30/20232,447-89-571-232N/A
6/30/20232,539-146-744-205N/A
3/31/20232,694-103-55740N/A
1/1/20232,667-119-576-49N/A
9/30/20222,69037-519-31N/A
6/30/20222,652119-542-29N/A
3/31/20222,536156-880-340N/A
1/1/20222,545205-999-262N/A
9/30/20212,523295-924-39N/A
6/30/20212,623466-613189N/A
3/31/20212,778634-335364N/A
12/31/20202,587667116622N/A
9/30/20202,532719187514N/A
6/30/20202,464713258515N/A
3/31/20202,181624203509N/A
12/31/20192,11158674428N/A
9/30/20192,04652979465N/A
6/30/20191,799377-1350N/A
3/31/20191,666271-28230N/A
12/31/20181,467164-10179N/A
9/30/20181,30973-11928N/A
6/30/20181,22665N/A7N/A
3/31/20181,20189N/A87N/A
12/31/20171,188100N/A102N/A
9/30/20171,149128N/A78N/A
3/31/20171,055109N/A108N/A
12/31/20161,082122N/A165N/A
12/31/201584050N/A15N/A
12/31/201477724N/A80N/A
12/31/201372334N/A40N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300702's forecast earnings growth (40.4% per year) is above the savings rate (2.8%).

Earnings vs Market: 300702's earnings (40.4% per year) are forecast to grow faster than the CN market (26% per year).

High Growth Earnings: 300702's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300702's revenue (18.6% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 300702's revenue (18.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 300702's Return on Equity is forecast to be high in 3 years time


Discover growth companies